As of November 6, 2026, Sana Biotechnology, Inc. is a publicly traded company (Nasdaq: SANA); its largest reported holder is Robert Nelsen, with 15.4% on Schedule 13G/A of August 14, 2026, then Fidelity (FMR) (12.5%). The largest insider holding is Steve Harr, the chief executive and president, with 8,960,751 shares (3.0% of shares outstanding), per Form 4 of March 10, 2026 (Schedule 13G/A, August 14, 2026).
Is this your company?
About to sign with, pay or invest in Sana Biotechnology, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Sana Biotechnology, Inc. a real, registered company?
- Sana Biotechnology, Inc. files with the SEC under CIK 1770121 (its SEC filings).
- Its shares are listed under the ticker SANA on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Seattle, Washington, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under SANA BIOTECHNOLOGY INC in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is Steven D. Harr, Director (Form 8-K filed 2026-04-24). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Fidelity (FMR) (filed 2026-11-05).
Who are Sana Biotechnology, Inc.'s owners and officers?
Sana Biotechnology, Inc.: incorporated in Delaware; business address in Seattle, Washington; industry Biological Products, (No Diagnostic Substances) (Schedule 13G/A, 2026-11-05).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-11-05 | Fmr LLC | 12.5% |
| Schedule 13G/A, 2026-08-14 | Robert Nelsen | 15.4% |
| Schedule 13G, 2026-05-21 | Ra Capital Management, L.P. | 6.3% |
| Schedule 13G, 2026-01-21 | Blackrock, Inc. | 5.1% |
| Schedule 13G/A, 2025-11-14 | Robert Nelsen | 17.3% |
Questions about who owns Sana Biotechnology, Inc.
Who owns Sana Biotechnology, Inc.?
On this page, 4 holders' latest ownership filings report 5% or more of Sana Biotechnology, Inc.: Robert Nelsen (15.4%, Schedule 13G/A, filed 2026-08-14), Fmr LLC (12.5%, Schedule 13G/A, filed 2026-11-05), Ra Capital Management, L.P. (6.3%, Schedule 13G, filed 2026-05-21) and Blackrock, Inc. (5.1%, Schedule 13G, filed 2026-01-21).
Who are the largest shareholders of Sana Biotechnology, Inc.?
By the share each holder's latest filing reports, the largest holders of Sana Biotechnology, Inc. on this page are Robert Nelsen (15.4%), Fmr LLC (12.5%) and Ra Capital Management, L.P. (6.3%).
When did Robert Nelsen buy into Sana Biotechnology, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Robert Nelsen on this page is the Schedule 13G/A, filed 2025-11-14, reporting 17.3%; its latest, Schedule 13G/A filed 2026-08-14, reports 15.4%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 5 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Sana Biotechnology, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Sana Biotechnology, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Sana Biotechnology, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
12 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-04-24 | Steven D. Harr | Director | departed |
Which insiders own Sana Biotechnology, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and president: 8,960,751 shares (3.0% of shares outstanding), 7,944,251 held directly and 1,016,500 indirectly (Form 4, 2026-03-10).
- , a director: 5,863,480 shares (2.0% of shares outstanding) (Form 4, 2026-10-06).
- Fidelity (FMR), a 10% owner: 4,541,572 shares (1.5% of shares outstanding), held indirectly through F-Prime Capital Partners Life Sciences Fund VI LP and 1 other (Form 4, 2025-01-10).
- Susan D. Wyrick: 196,196 shares (0.07% of shares outstanding) (Form 4, 2026-03-10).
- , the executive vice president and chief scientific officer: 183,352 shares (0.06% of shares outstanding) (Form 4, 2026-08-27).
Shares outstanding: 299,634,951 as of 2026-10-29, from the company's latest SEC cover page.
How much has Sana Biotechnology, Inc. raised?
No fundraising or offering filing from Sana Biotechnology, Inc. is on file with us.
Keep reading
More on Sana Biotechnology, Inc. and the records around it.
Sana Biotechnology, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Leadership changes Apr 2026
Companies that share a holder
- ARCH Venture Fund IX, L.P. also filed stake reports on 2 other companies: Vir Biotechnology, Inc. (Nov 2026), Lyell Immunopharma, Inc. (May 2026)
- RA Capital Management, L.P. also filed stake reports on 100 other companies: Climb Bio, Inc. (Nov 2026), Bambusa Therapeutics, Inc. (Nov 2026), SOLID BIOSCIENCES INC. (Nov 2026)
- FMR LLC also filed stake reports on 761 other companies: ASPEN NEUROSCIENCE INC (Nov 2026), AVALO THERAPEUTICS INC (Nov 2026), BRAZE INC (Nov 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/sana-biotechnology